Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

X4 Pharmaceuticals Inc (XFOR)

NASDAQ
Currency in USD
0.371
-0.022(-5.60%)
Closed
After Hours
0.361-0.010(-2.695%)
XFOR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
0.3600.400
52 wk Range
0.2611.600
Key Statistics
Edit
Prev. Close
0.393
Open
0.394
Day's Range
0.36-0.4
52 wk Range
0.261-1.6
Volume
1.96M
Average Volume (3m)
2.41M
1-Year Change
-46.89%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XFOR Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
2.684
Upside
+623.450%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

X4 Pharmaceuticals Inc Company Profile

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Compare XFOR to Peers and Sector

Metrics to compare
XFOR
Peers
Sector
Relationship
P/E Ratio
−3.8x−2.1x−0.7x
PEG Ratio
−0.050.000.00
Price/Book
1.1x1.7x2.6x
Price / LTM Sales
56.3x8.0x3.2x
Upside (Analyst Target)
-279.6%44.5%
Fair Value Upside
Unlock17.8%6.6%Unlock

Analysts' Recommendations

5 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2.684

(+623.53% Upside)

People Also Watch

0.9513
TPST
+0.14%
0.820
RENB
+8.41%
0.107
DBGI
-2.91%
1.1200
KITT
-7.44%
0.257
SYRS
-5.51%

FAQ

What Is the X4 Pharmaceuticals (XFOR) Stock Price Today?

The X4 Pharmaceuticals stock price today is 0.371

What Stock Exchange Does X4 Pharmaceuticals Trade On?

X4 Pharmaceuticals is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for X4 Pharmaceuticals?

The stock symbol for X4 Pharmaceuticals is "XFOR."

What Is the X4 Pharmaceuticals Market Cap?

As of today, X4 Pharmaceuticals market cap is 64.47M.

What is X4 Pharmaceuticals Earnings Per Share?

The X4 Pharmaceuticals EPS is -0.084.

What Is the Next X4 Pharmaceuticals Earnings Date?

X4 Pharmaceuticals will release its next earnings report on 12 Mar 2025.

From a Technical Analysis Perspective, Is XFOR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.